Policy & Medicine October 18, 2024
Thomas Sullivan

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and future drug innovations. Leading the discussion were Steve Ubl, President and CEO of PhRMA; Daniel O’Day, Chairman and CEO of Gilead Sciences; Robert Davis, Chairman and CEO of Merck; Sue Peschin, President and CEO of the Alliance for Aging Research; and Ted Okon, Executive Director of the Community Oncology Alliance. Together, these industry leaders provided critical insights into how the IRA may reduce access to medications for seniors while simultaneously undermining long-term biopharmaceutical innovation.

Impact on Medicare Part D: Less Access, Higher Costs

Steve Ubl opened the briefing by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
Survey Suggests Pharma Industry Still Struggling with Digital Transformation
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Putting Patients First by Extending the Reach of World-Class Care
Biotech startups are built on venture capital. Track funding rounds here.

Share This Article